Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for T1D and other autoimmune diseases, today announced that Breakthrough T1D has awarded a grant to Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida in support of PRISE-hATG, a clinical study evaluating SAB-142 in patients with Stage 3 T1D who are 100 days to 2 years from diagnosis. Stage 3 T1D is diagnosed when the disease has progressed to a point where insulin is required.

The PRISE-hATG study is designed to assess whether SAB-142 can preserve endogenous C-peptide and modulate immune responses in individuals with residual beta cell function beyond the first 100 days after a Stage 3 diagnosis. It extends SAB BIO’s clinical evaluation of SAB-142 and complements the ongoing Phase 2b SAFEGUARD trial evaluating SAB‑142 in patients with new onset Stage 3 T1D. SAB BIO will co-fund this study.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.